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Coronary Heart Disease
Novel Biomarker of Oxidative Stress Is Associated With Risk
of Death in Patients With Coronary Artery Disease
Riyaz S. Patel, MD; Nima Ghasemzadeh, MD; Danny J. Eapen, MD; Salman Sher, MD;
Shawn Arshad, MD; Yi-an Ko, PhD; Emir Veledar, PhD; Habib Samady, MD;
A. Maziar Zafari, MD, PhD; Laurence Sperling, MD; Viola Vaccarino, MD, PhD;
Dean P. Jones, PhD; Arshed A. Quyyumi, MD
Background—Free radical scavengers have failed to improve patient outcomes, promoting the concept that clinically
important oxidative stress may be mediated by alternative mechanisms. We sought to examine the association of emerging
aminothiol markers of nonfree radical mediated oxidative stress with clinical outcomes.
Methods and Results—Plasma levels of reduced (cysteine and glutathione) and oxidized (cystine and glutathione disulphide)
aminothiols were quantified by high performance liquid chromatography in 1411 patients undergoing coronary
angiography (mean age 63 years, male 66%). All patients were followed for a mean of 4.7±2.1 years for the primary
outcome of all-cause death (n=247). Levels of cystine (oxidized) and glutathione (reduced) were associated with risk of
death (P<0.001 both) before and after adjustment for covariates. High cystine and low glutathione levels (>+1 SD and
<−1 SD, respectively) were associated with higher mortality (adjusted hazard ratio [HR], 1.63; 95% confidence interval
[CI], 1.19–2.21; HR, 2.19; 95% CI, 1.50–3.19; respectively) compared with those outside these thresholds. Furthermore,
the ratio of cystine/glutathione was also significantly associated with mortality (adjusted HR, 1.92; 95% CI, 1.39–2.64)
and was independent of and additive to high-sensitivity C-reactive protein level. Similar associations were found for other
outcomes of cardiovascular death and combined death and myocardial infarction.
Conclusions—A high burden of oxidative stress, quantified by the plasma aminothiols, cystine, glutathione, and their ratio,
is associated with mortality in patients with coronary artery disease, a finding that is independent of and additive to the
inflammatory burden. Importantly, these data support the emerging role of nonfree radical biology in driving clinically
important oxidative stress.   (Circulation. 2016;133:361-369. DOI: 10.1161/CIRCULATIONAHA.115.019790.)
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xidative stress (OS) is implicated in the pathophysiology
of multiple conditions, including cardiovascular disease
(CVD).1 Although the harmful cellular effects of free radical
species in vitro remain undisputed, observational evidence
along with clinical trials of free radical scavengers has been
uniformly disappointing.2,3 This has promoted the concept that
free radicals may not constitute clinically important sources of
oxidants and that nonfree radical species may be of equal or
greater importance.4

◼

mortality

◼

oxidative stress

These covalent modifications serve to alter the cellular signaling activity of the proteins, thereby coupling redox modifications of aminothiols to functional activity.5 Importantly, these
aminothiols can be quantified in plasma to assess the oxidant
burden in vivo.6 Of these, cysteine constitutes the major aminothiol pool extracellularly that reacts readily with oxidants to
form its oxidized disulphide cystine. Intracellularly, glutathione is a major antioxidant that helps eliminate peroxides and
maintain cellular redox, and its oxidized form is glutathione
disulfide.4 Increased OS, measured as higher levels of cystine,
lower levels of glutathione, or altered ratios of oxidized to
reduced aminothiols, is associated with cellular dysfunction,
aging, risk factors for CVD, and subclinical vascular disease,
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Proteins are susceptible to oxidation through alterations of
reactive aminothiol residues such as cysteine and glutathione.
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and are likely to be reliable markers of systemic OS and antioxidant defense.7–13
However, there remains a need to determine whether oxidant burden as indicated by alterations in the levels or ratios of
these aminothiols is clinically relevant and determines adverse
outcomes. This would support the use of these aminothiols
as biomarkers of OS and potentially promote development
of novel antioxidant therapies. We thus sought to determine
whether the major aminothiols and their respective ratios
would be associated with increased mortality and cardiovascular events in a prospectively followed high-risk population.

Methods
Study Population
Study participants aged 20 to 90 years were recruited as part of the
Emory Cardiovascular Biobank, an ongoing prospective cohort of
patients enrolled prior to undergoing coronary angiography for investigation or management of coronary artery disease (CAD) across
three Emory Healthcare sites with collection of extensive data on
demographic characteristics, medical history, medication use, behavioral habits, and risk factor prevalence.14,15
Recruited patients were stable at the time of enrollment and
undergoing an elective procedure, although stable patients with
non–ST-segment–elevation myocardial infarction (MI), defined using
international criteria were also included and classified as acute MI.16
CAD burden was quantified using the semiquantitative Gensini score,
as previously described.16 Left ventricular function was expressed
using ejection fraction.17 Finally glomerular filtration rate (GFR)
was estimated using the Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) formula.18 Subjects were excluded if they
had a history of heart transplantation, recent transfusion, immunosuppressant use, malignancy, or significant infections or any vitamin
supplements in the previous 6 weeks. Specific dietary intake patterns were not documented but blood samples and measurements
were taken after an overnight fast before planned coronary angiography, except in <1% of patients who underwent angiography emergently on the same day. The study was approved by the Institutional
Review Board at Emory University, and all subjects provided written
informed consent.

Follow-Up and Outcomes
The cohort was prospectively followed for determination of the primary outcome of all-cause death and the secondary outcomes of cardiovascular death and the composite of death/or nonfatal MI. This
was performed by personnel blinded to aminothiol data, through telephone interview, chart review, and linkage with the Social Security
Death Index and state records. Cardiovascular death was defined as
death attributable to an ischemic cardiovascular cause (fatal MI, ischemic stroke, peripheral arterial disease) or sudden death attributable
to an unknown but presumed cardiovascular cause in high-risk CAD
patients. Medical records were accessed or requested to validate all
self-reported events including MI, which was defined using standard
criteria as above.16 Fifteen patients (1%) were lost to follow-up and
were excluded from analysis, leaving 1411 patients with complete
biomarker and follow-up data.

Measurement of Aminothiols and C-Reactive
Protein
We measured plasma cysteine (CyS), its oxidized form cystine
(CySS), glutathione (GSH), and its oxidized form glutathione disulphide (GSSG) in all subjects using high-performance liquid chromatography mass spectrometry. A full methods and protocol article has
been published previously outlining sample collection, processing,
and analysis steps in detail.6 Summary details are also presented in the
online-only Data Supplement, but briefly, arterial blood samples were
drawn via syringe immediately after placement of a femoral arterial

sheath (prior to heparin or saline flush or any coronary intervention)
and transferred into preprepared Eppendorf tubes containing preservatives to retard auto-oxidation, centrifuged, and stored at −80°C
for no more than 2 months before transfer to the laboratory. Sample
collection and storage conditions in this way have been previously
verified.6 Analyses by high-performance liquid chromatography were
performed after dansyl derivatization on a 3-aminopropyl column
with fluorescence detection. Metabolites were identified by coelution
with standards and quantified by integration relative to the internal
standard, with validation relative to external standards as previously
described.6 Ratios of oxidized to reduced aminothiols (cystine/cysteine and glutathione disulphide/glutathione) are expressed directly.
The coefficients of variation for each of the aminothiols were as follows: cysteine 3.8%, cystine 3.2%, glutathione 5%, and glutathione
disulphide 9.7%. High-sensitivity C-reactive protein (hsCRP) levels
were quantified using a sandwich immunoassay (R&D Systems,
Minneapolis, MN). Minimum detectable hsCRP concentrations were
0.1 mg/l.

Statistical Methods
Continuous variables are presented as means±SD or as median (interquartile range) and categorical variables as proportions (%) with
one-way analysis of variance and chi-squared tests used to determine
differences between groups.
Before analysis, aminothiol measures were non-normally distributed and were natural log +1 transformed. Furthermore, to make the
effects comparable between markers, the log-transformed variables
were standardized to have mean 0 and SD 1. They were assessed as
continuous and categorical traits, initially by per unit log increase and
per SD increment and then by a 1×SD cut-off to classify high and low
values. Survival analysis was performed using Kaplan–Meier curves
as well as Cox proportional-hazards regression in models adjusted
first for age, gender, and then additionally for body mass index (kg/
m2), GFR (l/min), presence of diabetes mellitus, hypertension, total
cholesterol (mg/dL), high-density lipoprotein (mg/dL), current
smoking, statin use, acute MI at enrollment, left ventricular function
(ejection fraction; %), Gensini score, and plasma hsCRP at baseline.
Given that inflammation and oxidative stress are biologically interrelated, an interaction term between hsCRP and each of the markers
(including their ratios) was initially included in the model. Interaction
between age and each marker was also considered to examine any
potential age-modifying effects. Missing covariate data (range, 0% to
3%) were imputed and sensitivity analysis with unimputed data found
results to be similar. The proportional hazards assumption for Cox
models was evaluated by plots of Schoenfeld residuals and formal
testing (a χ2 test calculated as the sum of Schoenfeld residuals), with
no significant violations of the assumption found.
The incremental value of the aminothiol markers for risk prediction was tested before and after their addition to a clinical model with
traditional risk predictors (age, gender, body mass index, GFR, diabetes mellitus, hypertension, total cholesterol, high-density lipoprotein, current smoking, statin use, acute MI, left ventricular function,
Gensini score). The C-statistic and category-free net reclassification
improvement as well as integrated discrimination improvement that
can account for censored data were calculated as a measure of risk
discrimination.19–22 We set the truncation time at 5 years. The resulting risk discrimination metrics indicate the performance of the given
model in predicting events that occurred in the time range from baseline to 5 years. P values <0.05 from 2-sided tests were considered to
indicate statistical significance. Statistical analyses were performed
using SPSS 20.0 (Chicago, IL), SAS (Cary, NC), and R (3.1.0).

Results
Baseline characteristics of the 1411 patients are presented in
Table 1 and were reflective of a typical population recruited at
coronary angiography. The mean age of the cohort was 63.2
(±11.3) years, 66% male, 32% with diabetes mellitus, 69%
with hypertension or hyperlipidemia, and 16% were current
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smokers. Approximately 72% had significant CAD (>50%
luminal stenosis) on angiography, 14% had presented with
evidence of acute MI (all stable non–ST-segment–elevation
MI), and 46% were treated with revascularization during the
admission at which they were enrolled (Table 1).

Relationship Between Aminothiols
The oxidized aminothiol, cystine was almost 8-fold more
abundant than its reduced form cysteine, whereas the
reduced aminothiol glutathione was 40 times more abundant than its oxidized form glutathione disulphide (Table 1).
There were modest correlations between the various aminothiols, whereas hsCRP was only marginally associated
with the aminothiol markers (Table I in the online-only Data
Supplement).
Table 1.

Relationship Between Aminothiols and
Demographic and Clinical Features
In univariate analyses, higher plasma cystine levels (high OS)
were associated with older age, female gender, higher body
mass index, impaired renal function (lower GFR), presence of
diabetes mellitus, hypertension, lower total cholesterol levels,
statin use, impaired left ventricular function (lower ejection
fraction), greater CAD burden (Gensini), and greater inflammation (hsCRP). Of these, only age, sex, body mass index,
GFR, diabetes mellitus, and hypertension were independently
associated with plasma cystine in a multivariate model. Higher
glutathione levels (less OS) were associated with younger
age, lower GFR, absence of diabetes mellitus and hypertension, lower CAD burden, and higher total cholesterol. Of these
only age, GFR, CAD burden, and total cholesterol remained

Patient Characteristics
All (N=1411)

No Event (n=1164)

Event (n=247)

Clinical characteristics
Age, y

63.2 (11.3)

62.0 (11.1)

69.0 (11.0)

Male, %

66.3

66.2

66.8

Caucasian, %

85.7

85.2

88.3

BMI, kg/m2

29.9 (6.41)

30.2 (6.4)

28.5 (6.4)

GFR, ml/min

73.1 (21.6)

75.3 (20.2)

62.5 (24.6)

Hypertension, %

68.9

66.9

78.1

Hyperlipidemia, %

68.4

67.8

71.7

Total cholesterol, mg/dL

172.2 (45.7)

174.4 (45.7)

161.4 (44.1)

LDL, mg/dL

99.6 (38.5)

101.4 (39.2)

91.2 (34.5)

HDL, mg/dL

41.2 (12.3)

41.4 (12.1)

40.3 (13.2)

Diabetes mellitus, %

32.2

29.9

43.3

Current smoking, %

16.4

16.4

16.6

Acute MI, %
LVEF, %

14.3

13.2

19.8

53.7 (11.9)

54.9 (10.8)

48.0 (15.3)

71.5

69.8

81.9

Angiographic CAD
Significant >50%, %
Normal <10%, %

19.1

20.9

8.7

14.5 (1–51)

13.0 (0–44)

28 (5–121)

46

44.8

52.5

Statin use, %

74.4

74.6

73.1

Aspirin use, %

83

83.4

81.4

ACE or ARB use, %

62.7

62.3

64.9

Beta blocker use, %

63.8

62.2

71.5

2.9 (1.2–7.1)

2.6 (1.2–6.4)

4.7 (1.75–14.0)

Cystine, μmol/L

97.6 (83.3–115.0)

96.1 (82.3–112.3)

106.9 (90.4–130.6)

Cysteine, μmol/L

12.2 (10.1–14.7)

12.2 (10.1–14.4)

12.3 (9.6–16.1)

Glutathione, μmol/L

1.17 (0.92–1.47)

1.19 (0.94–1.48)

1.07 (0.82–1.43)

Glutathione disulphide, μmol/L

0.02 (0.01–0.03)

0.02 (0.01–0.03)

0.02 (0.02–0.04)

Median Gensini Score (IQR)
Revascularization at Enrollment, %
Medication use

Inflammation (median, IQR)
C-reactive protein, mg/L
Oxidative stress (median, IQR)

Mean (SD) values, median (IQR) values and % shown unless stated. ACE indicates angiotensin converting
enzyme; ARB, angiotensin receptor blocker; BMI, body mass index; CAD, coronary artery disease; GFR,
glomerular filtration rate; HDL, high-density lipoprotein; IQR, interquartile range; LDL, low-density lipoprotein;
LVEF, left ventricular ejection fraction; and MI, myocardial infarction.
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independently associated with plasma glutathione. Higher
cysteine levels also correlated independently with GFR, diabetes mellitus, CAD burden, and total cholesterol whereas
glutathione disulfide did not show any associations aside from
an inverse association with GFR (Table IIA and IIB in the
online-only Data Supplement).

Relationships Between Individual Aminothiols and
Outcomes
During a mean follow-up of 4.7 (±2.1) years (median, 5.3;
interquartile range, 3.1–6.2), representing 6570 person-years
of follow-up, 247 patients experienced the primary outcome of
death, of which there were 169 cardiovascular deaths and 314
composite outcomes of death/MI. Patients who experienced
the primary outcome were generally older and had more risk
factors and disease burden as shown in Table 1. Independent
clinical predictors of outcomes are presented in Table III in the
online-only Data Supplement.
The baseline cystine (P<0.001) and glutathione (P=0.002)
levels were both associated with risk of future death after
adjustment for age and sex (log values, Table 2). These associations persisted after further adjustment for important covariates
(see methods) including hsCRP (P=0.001 and P=0.006, respectively). After standardization, to permit marker comparisons, a
1-SD increment in cystine and a 1-SD decrease in glutathione
was associated with a 26% and 20% increase in risk of death
after adjustment for all risk factors, respectively (Table 2).
This association was also evident when cystine and glutathione levels were categorized into quartiles (Kaplan–Meier
log rank P<0.001 and P=0.002, respectively; Figure I and
Table IV in the online-only Data Supplement). Examination
of the Kaplan–Meier plots revealed a possible threshold
effect, especially for glutathione.

Table 2.
Events

Relationship Between Aminothiol Ratios and
Outcomes
We also examined the ratio of cystine to glutathione, as a
novel measure of extracellular oxidation to intracellular reducing capacity and demonstrated a highly significant association with the primary outcome (P<0.001; Table 3, Figure 1).
Patients with a >+1SD level of cystine/glutathione ratio,
reflecting a high extracellular oxidant burden and low intracellular reducing capacity, demonstrated a HR of 1.92 (95%

Cox Regression Survival Analysis for the Individual Aminothiol Markers Showing Significant Association With Adverse
Continuous (log)
HR (95% CI)

Aminothiol
Cystine (oxidized)

Glutathione
(reduced)

We further explored this by using a 1-SD cut point
to define high and low levels of aminothiol markers (see
Methods). Survival analysis confirmed a worse prognosis for
patients with high cystine (>+1SD; >129.8 μmol/L) and for
those with low glutathione (<−1SD, <0.68 μmol/L) levels (log
rank P<0.001 for both; Figure 1). Both a high cystine level
and low glutathione level were each associated with a 2- to
3-fold increase in age and sex adjusted risk of death (hazard
ratio [HR], 2.05; 95% confidence interval [CI],1.53–2.75; HR,
3.16; 95% CI, 2.20–4.54; respectively). After adjustment for
all covariates, a high cystine level was associated with a HR of
1.63 (95% CI, 1.19–2.21) and a low glutathione level of 2.19
(95% CI, 1.50–3.19).
Importantly, both cystine and glutathione were independently associated with the primary outcome of death, when
entered into the same multivariate model. Furthermore, both
of these aminothiols were also associated with the secondary
outcomes of cardiovascular death and the composite of death
and MI (Table 2). Glutathione in particular showed a greater
effect size for cardiovascular death compared to all-cause
death. However, their respective couples, cysteine (reduced)
and glutathione disulphide (oxidized) were not associated
with the outcomes examined (data not shown).

Fully Adjusted Model
2.42 (1.40–4.17)
P=0.001

1.44 (1.25–1.64)
P<0.001

Death/MI (n=314) 3.15 (1.99–4.99)
P<0.001

2.06 (1.28–3.32)
P=0.003

CV Death (n=169) 3.90 (2.07–7.33)
P<0.001

Categorized (High Versus Low)
HR (95% CI)

Fully Adjusted Model

Age- and
Sex-Adjusted

Fully Adjusted Model

1.26 (1.09–1.45)
P=0.001

2.05 (1.53–2.75)
P<0.001

1.63 (1.19–2.21)
P=0.002

1.35 (1.20–1.52
P<0.001)

1.21 (1.07–1.37)
P=0.003

1.88 (1.44–2.46),
P<0.001

1.54 (1.16–2.04),
P=0.003

2.06 (1.07–3.96)
P=0.031

1.42 (1.21–1.68)
P<0.001

1.21 (1.02–1.43)
P=0.031

2.16 (1.52–3.07)
P<0.001

1.63 (1.12–2.36)
P=0.010

1.82 (1.42–2.33)
P<0.001

1.57 (1.22–2.02)
P=0.001

1.24 (1.08–1.43)
P=0.002

1.20 (1.05–1.37)
P=0.006

3.16 (2.20–4.54)
P<0.001

2.19 (1.50–3.19)
P<0.001

Death/MI (n=314) 1.73 (1.38–2.17)
P<0.001

1.51 (1.20–1.90)
P<0.001

1.23 (1.08–1.39)
P=0.001

1.20 (1.06–1.34)
P=0.003

2.66 (1.89–3.74)
P<0.001

1.89 (1.32–2.70)
P<0.001

CV Death (n=169) 1.88 (1.40–2.53)
P<0.001

1.63 (1.20–2.20)
P=0.002

1.21 (1.03–1.43)
P=0.023

1.18 (1.01–1.38)
P=0.041

3.63 (2.39–5.50)
P<0.001

2.53 (1.63–3.92)
P<0.001

Outcome

Death (n=247)

4.02 (2.38–6.78)
P<0.001

HR (95% CI)
Age- and
Sex-Adjusted

Death (n=247)

Age- and
Sex-Adjusted

Standardized (per SD)

Cox regression analysis of aminothiol markers as continuous and categorized measures, with risk of adverse outcomes. Cystine categorized as high if >+1 SD and
low if ≤+1 SD; Glutathione categorized as low if <−1SD and high if ≥−1 SD; Cysteine (reduced) and Glutathione disulphide (oxidized) did not show any significant
associations (data not shown). Full model includes adjustment for age, sex, body mass index, glomerular filtration rate, diabetes mellitus, hypertension, total cholesterol,
high-density lipoprotein, current smoking, statin use, acute myocardial infarction, left ventricular ejection fraction, Gensini score, and Ln C-reactive protein. CI indicates
confidence interval; CV, cardiovascular; HR, hazard ratio; and MI, myocardial infarction.
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Figure 1. Kaplan–Meier curves for association between high vs low levels of cystine, glutathione, and the cystine/glutathione ratio. High
vs low categorization was defined by SD cut off (see Methods). Log rank P values and number of patients within each category are
shown.

CI, 1.39–2.64) for death after full adjustment for all covariates
(Table 3). Similar significant associations were noted for the
secondary outcomes of cardiovascular death (HR, 1.91; 95%
CI, 1.34–2.72) and the composite of death/MI (HR, 1.88; 95%
CI, 1.40–2.52).
In contrast, although the direct ratios within the extracellular and intracellular compartments of cystine (oxidized) to
cysteine (reduced) and glutathione disulphide (oxidized) to
glutathione (reduced) were associated with the studied outcomes in adjusted models, the associations were attenuated in
comparison with those for cystine, glutathione, or the cysteine/glutathione ratio (Table 3).

CAD and MI Subgroup Analyses
There was no significant heterogeneity in the association
between the cystine/glutathione ratio and adverse events
based on baseline characteristics. Thus, among patients with
obstructive CAD, those with high cystine/glutathione ratio
had a HR of 1.80 (95% CI, 1.27–2.54) in comparison with
3.11 (95% CI, 1.19–8.15) for those with nonobstructive CAD.
Although there was no significant interaction, the risk of a high
cystine/glutathione ratio was higher in those with acute MI in
comparison with those without, HR 3.87 (95% CI, 1.74–8.63)
and HR 1.82 (95% CI, 1.26–2.62), respectively.

Inflammation and Oxidant Stress
Given that no significant interaction between hsCRP and each
of the markers (including their ratios) was found (results not
shown) and both hsCRP and the cystine/glutathione ratio were
independently associated with risk of death, we devised a simple multi-marker score, using high/low categories to identify
the potential value of combining inflammation and OS measures for predicting future events. A score of 0 (n=647) represented both low inflammation (low hsCRP, defined as <3
mg/L [median])23 and low OS (low cystine/glutathione ratio
[by SD as above]), whereas a score of 2 reflected both high
hsCRP and high cystine/glutathione (n=84). A score of 1 was
given to the remaining 661 subjects (Figure 2). In comparison
with those with a score of 0, those with a score of 1 had a
covariate adjusted HR of 1.46 (95% CI, 1.08–1.97) for risk
of death, whereas those with a score of 2 had a HR of 3.26
(95% CI, 2.17–4.90). Thus, patients with a score of 0, 1, or 2

experienced a 1-year death rate of 1.1%, 4.9%, or 14.5% or
a 5-year event rate of 9.7%, 17.3%, and 41.5%, respectively.

Discrimination Testing
When compared with a standard model for risk of death, consisting of traditional risk factors (see Methods), the addition
of hsCRP, hsCRP + the ratio of cystine/glutathione, and the
combination of these 2 biomarkers as a multi-marker score
improved the risk discrimination significantly, including
C-statistic, net reclassification improvement, and integrated
discrimination improvement (Table 4). Specifically, whereas
addition of the individual aminothiols cystine or glutathione
did not improve risk discrimination, the ratio of cystine/glutathione improved both the net reclassification improvement
(HR, 0.109; 95% CI, 0.011–0.176) and integrated discrimination improvement (HR, 0.012; 95% CI, 0.001–0.029; Table 4).

Discussion
Herein we demonstrate that the plasma aminothiols cystine
and glutathione associate with risk of future death in a highrisk population with CAD. This effect is independent of,
and additive to, that of inflammation as assessed by hsCRP.
Quantification of plasma aminothiol markers may thus represent an important advance for in vivo assessment of clinically
important OS.
Specifically, we show that patients with high OS captured
as (1) a high level of oxidized cystine, representing greater
extracellular oxidant burden, (2) a low level of reduced glutathione, representing low intracellular reducing capacity, or (3)
a high ratio of the 2, have a 2-fold increase in risk of mortality over a mean of 5 years independent of age and other risk
factors including inflammation. Whereas previous attempts
at quantifying aminothiol mediated OS have used the redox
potential of cystine or glutathione disulphide using the Nernst
equation,6 we found that the directly combined, cross compartment ratio of cystine to glutathione is simple and practical
to calculate and able to discriminate risk, thus representing
an improved approach to capturing the overall burden of OS
in vivo.
Control of protein redox state via thiol-disulfide switching is critical for normal cellular activities and for maintaining physiological and pathophysiological functions including

366  Circulation  January 26, 2016
Table 3.
Death

Cox Regression Survival Analysis for Oxidized to Reduced Ratios of Aminothiol Markers With the Primary Outcome of

Aminothiol Ratio
Cystine/Glutathione
ratio

Cystine/Cysteine
ratio

Glutathione
disulphide/
Glutathione ratio

Continuous (log)

Standardized (per SD)

Categorized (High v Low)

HR (95% CI), P Value

HR (95% CI), P Value

HR (95% CI), P Value

Age- and
Sex-Adjusted

Fully Adjusted Model

Age- and
Sex-Adjusted

Fully Adjusted Model

Age- and
Sex-Adjusted

Fully Adjusted Model

2.16 (1.65–2.82)
P<0.001

1.74 (1.34–2.27)
P<0.001

1.47 (1.29–1.68)
P<0.001

1.32 (1.16–1.50)
P<0.001

2.26 (1.65–3.09)
P<0.001

1.92 (1.39–2.64)
P<0.001

Death/MI (n=314) 1.97 (1.56–2.49)
P<0.001

1.65 (1.31–2.08)
P<0.001

1.40 (1.25–1.58)
P<0.001

1.29 (1.14–1.44)
P<0.001

2.17 (1.63–2.90)
P<0.001

1.88 (1.40–2.52)
P<0.001

CV Death (n=169) 2.13 (1.59–2.86)
P<0.001

1.66 (1.21–2.28)
P=0.002

1.45 (1.24–1.71)
P<0.001

1.29 (1.10–1.51)
P=0.002

2.31 (1.58–3.36)
P<0.001

1.91 (1.34–2.72)
P<0.001

1.87 (1.28–2.73)
P<0.001

1.50 (1.05–2.15)
P=0.027

1.23 (1.09–1.40)
P=0.001

1.15 (1.02–1.29)
P=0.027

1.72 (1.24–2.39)
P=0.001

1.36 (0.97–1.91)
P=0.07

Death/MI (n=314) 1.78 (1.27–2.51)
P=0.001

1.50 (1.08–2.08)
P=0.015

1.21 (1.08–1.36)
P=0.001

1.14 (1.03–1.28)
P=0.015

1.57 (1.15–2.12)
P=0.004

1.31 (0.96–1.80)
P=0.09

CV Death (n=169) 1.72 (1.09–2.71)
P=0.021

1.32 (0.86–2.04)
P=0.20

1.20 (1.03–1.39)
P=0.021

1.10 (0.95–1.27)
P=0.20

1.74 (1.12–2.58)
P=0.006

1.30 (0.87–1.95)
P=0.21

1.34 (1.12–1.60)
P=0.001

1.21 (1.01–1.46)
P=0.035

1.22(1.10–1.37)
P=0.001

1.14 (1.01–1.29)
P=0.035

1.59 (1.10–2.29)
P=0.014

1.36 (0.93–1.98)
P=0.111

Death/MI (n=314) 1.41 (1.20–1.65)
P<0.001

1.31 (1.12–1.53)
P=0.001

1.25 (1.13–1.39)
P<0.001

1.20 (1.08–1.33)
P=0.001

1.78 (1.29–2.45)
P<0.001

1.55 (1.11–2.14)
P=0.009

CV Death (n=169) 1.37(1.07–1.699)
P=0.004

1.22 (0.98–1.53)
P=0.07

1.23 (1.07–1.42)
P=0.004

1.14 (0.99–1.32)
P=0.074

1.70 (1.10–2.62)
P=0.017

1.43 (0.92–2.24)
P=0.11

Outcome
Death (n=247)

Death (n=247)

Death (n=247)

Cox regression analysis of aminothiol marker ratios as continuous and categorized measures, with risk of adverse outcomes. All ratios categorized as high if >+1
SD and low if ≤+1 SD. Full model includes adjustment for age, sex, body mass index, glomerular filtration rate, diabetes mellitus, hypertension, total cholesterol, highdensity lipoprotein, current smoking, statin use, acute myocardial infarction, left ventricular ejection fraction, Gensini score, and Ln C-reactive protein. CI indicates
confidence interval; CV, cardiovascular; HR, hazard ratio; and MI, myocardial infarction.

promotion of CVD. This includes (1) experimental evidence
for effects on proinflammatory signaling, mitochondrial oxidation, nuclear factor KB activation, and elevated expression
of genes for monocyte recruitment to endothelial cells5,7,8,24;
(2) association with clinical risk factors such as aging, obesity,
and smoking9,25,26; (3) translational studies confirming association between aminothiols and worse endothelial function,
carotid intima media thickness, and arterial stiffness11,27,28;
and (4) prospective outcome data in patients at high CVD risk
as presented here. In totality, these findings support the use
of plasma levels of oxidized and reduced aminothiols as key
biomarkers of OS and cellular health and potentially as new
therapeutic targets.
The utility of these aminothiols in clinical practice requires
further testing. Whereas addition of cystine and glutathione
individually did not improve risk discrimination beyond a
standard clinical model, addition of the cystine/glutathione
ratio did improve both risk reclassification metrics. Given the
interplay between inflammation and OS at a molecular level,
and with additive effect on risk, we devised and tested a simple multi-marker score combining the biomarkers of each, for
ease of clinical use. This simple 3-point score clearly stratified risk and when added to a clinical model also improved
the C-statistic and metrics of risk reclassification. Thus, a
combination of biomarkers, in this case reflecting aminothiolmediated OS and inflammation-quantified by CRP, may offer
a valuable approach for clinical risk stratification as has been
recently described.14

Mechanistically, these findings may have implications for
understanding other observations. Homocysteine, an important aminothiol, is biosynthesized from dietary methionine,
and in the presence of folate and B vitamins converts to cysteine by cystathione synthase (Figure II in the online-only Data

Figure 2. Covariate adjusted survival analysis for the multimarker score by Cox regression, combining low vs high hsCRP
(inflammation) and low vs high cystine/glutathione ratio (oxidative
stress [OS]). A score of 0 (blue line, n=647) represents low
inflammation and low OS, whereas a score of 2 (red line, n=84)
represents high inflammation and high OS. A score of 1 (green
line, n=661) represents either high inflammation or high OS only.
hsCRP indicates high-sensitivity C reactive protein.
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Table 4. Estimates and the Corresponding 95% Confidence Limits for the Risk Discrimination Metrics (Change
in C-Statistic, NRI, and IDI) for the Primary Outcome of Death Within Five Years of Follow-Up
Models
Clinical Model

C-Statistic

∆C-Statistic

Category-Free NRI

Relative IDI

0.717 (0.674, 0.761)

—

—

—

+ CRP

0.736 (0.692, 0.779)

0.018 (0.003, 0.034)

0.109 (0.023, 0.203)

+ Cystine (CySS)

0.722 (0.678, 0.766)

0.005 (-0.003, 0.013)

0.046 (-0.041, 0.132)

0.0202 (0.006, 0.04)
0.006 (-0.001, 0.020)

+ Glutathione (GSH)

0.724 (0.688, 0.759)

0.006 (-0.004, 0.017)

0.084 (-0.026, 0.157)

0.005 (-0.001, 0.017)

+ CySS/GSH Ratio

0.728 (0.695, 0.762)

0.011 (-0.002, 0.024)

0.109 (0.011, 0.176)

0.012 (0.001, 0.029)

+ CRP + CySS/GSH Ratio

0.746 (0.708, 0.785)

0.029 (0.009, 0.049)

0.133 (0.044, 0.214)

0.032 (0.013, 0.059)

+ Multi-marker score*

0.736 (0.702, 0.769)

0.018 (0.002, 0.035)

0.124 (0.026, 0.191)

0.018 (0.004, 0.043)

Clinical model includes age, sex, body mass index, glomerular filtration rate, diabetes mellitus, hypertension, current smoking, acute
myocardial infarction, Gensini score, left ventricular ejection fraction, statin use, total cholesterol, and high-density lipoprotein. CRP indicates
C reactive protein; IDI, integrative discriminatory improvement; and NRI, net reclassification improvement.
*Multi-marker score is scored 0, 1, and 2 based on combinations of high or low C-reactive protein and high or low cystine/glutathione ratio.

Supplement). While patients with genetic hyperhomocystinemia are prone to severe atherosclerosis, folate supplementation and homocysteine reduction does not appear to reduce
CVD risk.29,30 This may be because cysteine is independently
maintained from homocysteine and represents a more abundant and reactive aminothiol that on oxidation forms cystine,
which is 30 times more abundant than homocysteine and
perhaps is a more pathological component. Although some
studies have shown association between total cysteine and
CVD,31,32 none until now has examined the individual oxidized and reduced components or their respective contribution to the oxidant burden. These data may thus offer a partial
explanation for the failure of homocysteine targeted therapy
and possible new treatment opportunities.
Although experimental data support the role of free radical biology in OS, clinical attempts at improving outcomes
with free radical scavengers (vitamins C, E, etc) have been
uniformly disappointing.2,33 Our findings support the hypothesis that in vivo, OS may also be driven by nonfree radical
processes, raising the possibility that alternative antioxidative
therapies may be more effective. In humans there is no currently known pathway to reduce cystine to cysteine, although
cystine levels are in part controlled by the Xc system acting
as a highly efficient glutamate-cystine transporter.34 Cellular
expression of this transporter declines with age, potentially
explaining the association with cystine and age that we and
others have observed. In contrast zinc enhances expression
of this system and could represent a therapeutic option to
reduce plasma cystine and OS. Indeed a recent pilot study in
patients with macular degeneration has revealed reductions in
plasma levels of oxidized cystine with zinc supplementation,
suggesting that levels can be manipulated with therapeutic
interventions.35

Strengths and Limitations
Strengths of our study include its prospective design, large
sample size, exploration of both reduced and oxidized aminothiols, long follow-up, use of robust clinical outcomes, and
exploration of the interaction with inflammation assessed by
hsCRP. We did not have dietary information on our subjects,
and ingestion of sulfur-rich amino acids may influence plasma
aminothiol levels. However, after a meal, cysteine shows rapid

distribution and cystine levels increase for 2 to 3 hours and
almost all of our patients were fasting for >8 hours, which
minimized the likely dietary changes on aminothiol levels. We
did not have detailed drug information to explore whether thiol
containing medications impacted on measured levels, and it is
possible that some patients taking these drugs may have nonrepresentative levels. Our population is also not representative
of all populations, and thus our findings may not be generalizable, and require further validation in different groups.
Finally, as an observational study we cannot infer causality, and confounding by CAD remains possible. Nonetheless,
oxidative stress is an accepted mechanism for plaque development and previous associations with upstream risk factors
and subclinical phenotypes in those without CAD, as well as
sensitivity analysis in those with and without CAD showing a
consistent effect in both groups, suggests reverse causation is
less likely. However confounding can never be fully excluded
without interventional studies, but even if causality is not confirmed, this does not limit the value of these thiols for use
as biomarkers of intracellular and extracellular oxidative
stress, analogous to use of CRP as a biomarker of systemic
inflammation.

Conclusions and Implications
A high extracellular oxidant burden or reduced intracellular
antioxidant capacity quantified through assessment of plasma
aminothiols is associated with higher mortality in patients
with CAD. As well as representing potentially novel therapeutic targets, OS measured in this way could complement risk
stratification in conjunction with assessment of inflammation
assessed by hsCRP. Further studies will evaluate non–highperformance liquid chromatography methods of aminothiol
assessments to facilitate their wider use as biomarkers and to
investigate whether therapies such as zinc supplementation,
seeking to reduce plasma cystine can alter OS and improve
outcomes.
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Clinical Perspective
Although oxidative stress is a critically important process in atherosclerosis, observational evidence and clinical trials of
free radical scavengers have proven uniformly disappointing. This has promoted the concept that clinically important oxidative stress may be mediated by nonfree radical species. Proteins with reactive aminothiols are susceptible to oxidation, and
quantification of these reduced and oxidized (redox) residues offers an alternative means of quantifying in vivo oxidative
stress and oxidant burden. Having developed means to reliably collect and quantify these markers in plasma, we have previously shown associations with multiple risk factors for cardiovascular disease as well as with subclinical markers such as
arterial stiffness and intima media thickness. However, whether these markers are clinically relevant has remained unknown.
In this study, we now present long-term outcome data demonstrating association between these redox markers and adverse
cardiovascular outcomes and mortality. These findings are important as they support the use of these aminothiols as novel
and reliable biomarkers of oxidative stress. Importantly, given that oxidation of these aminothiols leads to altered cellular
signaling, these findings may offer new opportunities for therapeutic interventions for reducing the adverse clinical impact
of oxidative stress in vivo.

